Anti-inflammatory and Anti-helminthic potential of Methanolic and Aqueous extract of Polygonum alpinum rhizomes

Aim: The present research work was carried out to evaluate the anti-inflammatory and anthelminthic activity of the extracts of Polygonum alpinum rhizomes. Methods: Fresh rhizomes of the P. alpinum were collected, washed and shade dried. The methanolic and aqueous extracts were first tested for phytochemical screening. In-vitro anti-inflammatory activities of crude extracts were evaluated by HRBC (Human Red Blood Cell) membrane stabilization method and percentage inhibition of protein denaturation method. Similarly anti-helminthic activity was evaluated using earthworms of 6-8 cm in length and 0.3-0.4 cm in width and the results were compared with standard drug Albendazole. Results: Phytochemical analysis of the extract reveals the of presence of Carbohydrates, Cardiac glycosides, Coumarins, proteins,  amino acids, flavonoids, saponins, steroids, terpenoids, tannins and phenolics. The methanolic extract showed potent membrane stabilizing and significantly inhibit protein denaturation as compared to standard indomethacin. Methanolic extract at the concentration of 125μg/mL showed 81.29% membrane stabilizing activity as compared to aqueous extract 64.72%. Standard indomethacin showed 95.56 % activity at the same concentration. Similarly, methanolic extract at 500μg/mL showed 72.70% inhibition of protein denaturation as compared to aqueous extract 64.72%. Standard indomethacin showed 88.26% inhibition of protein denaturation at the same concentration. Both the methanolic and aqueous extracts showed dose dependent anthelminthic activity as compared to standard Albendazole. Conclusion: These results suggest that both the extracts from P. alpinum have promising anti-inflammatory and anthelmintic activity and that more broadly; plant extracts are a potential rich source of anti-inflammatory and anthelmintics to combat these diseases

Amelioration of experimental hyperlipidemia in rats by Portulaca oleracea Linn from Kashmir Himalaya

Background: Traditionally, Portulaca oleracea Linn. treats abscesses and dysentery as well as liver disease. Additionally, recent studies have reported its effectiveness as a neuroprotective, analgesic, anti-inflammatory, bronchodilator, anti-cancer, antioxidant, and curative, in addition to its pharmacological effects. Aim and Objective: To assess the phytochemical constituents quantitatively & qualitatively and lipid-lowering potential of different extracts of Portulaca oleracea L. from Kashmir Himalaya. Methods: Portulaca oleracea L. was extracted with chloroform, methanol, and aqueous solvents. Qualitative and quantitative phytochemical screening was carried and antihyperlipidemic activity was evaluated in experimental hyperlipidemic rats fed with cholesterol in coconut oil for 14 days. Results: Chloroform, methanol, and aqueous extracts showed the presence of alkaloids, sapon ins, tannins, cardiac glycosides, terpenes, flavonoids, phenolic compounds, proteins, and carbohydrates. Quantitatively the dried plant powder contains alkaloids 0.72 g%, saponins 1.0 g%, phenolics 1.09 g%, tannins 0.91 g%, carbohydrates 0.53 g%, proteins 0.25 g% and lipids 0.87 g%. The aqueous extract was found to decrease the plasma total cholesterol, triglyceride, low-density lipoprotein-cholesterol, very lowdensity lipoprotein-cholesterol levels, LDL-C/HDL-C ratio and significantly elevated the high-density lipoprotein-cholesterol levels as compared to methanol and chloroform extracts against cholesterol-induced hyperlipidemic rats. Conclusions: The results reveal that the Portulaca oleracea L. from the Kashmir region possesses alkaloids, saponins, phenolics, tannins, carbohydrates, proteins and lipids and aqueous extract of Portulaca oleracea L. at a dose of 200 mg/kg body weight possess highly significant antihyperlipidemic action than methanolic and chloroform extracts at similar doses

Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects

Abstract Cancer poses a significant global health challenge, with predictions of increasing prevalence in the coming years due to limited prevention, late diagnosis, and inadequate success with current therapies. In addition, the high cost of new anti-cancer drugs creates barriers in meeting the medical needs of cancer patients, especially in developing countries. The lengthy and costly process of developing novel drugs further hinders drug discovery and clinical implementation. Therefore, there has been a growing interest in repurposing approved drugs for other diseases to address the urgent need for effective cancer treatments. The aim of this comprehensive review is to provide an overview of the potential of approved non-oncology drugs as therapeutic options for cancer treatment. These drugs come from various chemotherapeutic classes, including antimalarials, antibiotics, antivirals, anti-inflammatory drugs, and antifungals, and have demonstrated significant antiproliferative, pro-apoptotic, immunomodulatory, and antimetastatic properties. A systematic review of the literature was conducted to identify relevant studies on the repurposing of approved non-oncology drugs for cancer therapy. Various electronic databases, such as PubMed, Scopus, and Google Scholar, were searched using appropriate keywords. Studies focusing on the therapeutic potential, mechanisms of action, efficacy, and clinical prospects of repurposed drugs in cancer treatment were included in the analysis. The review highlights the promising outcomes of repurposing approved non-oncology drugs for cancer therapy. Drugs belonging to different therapeutic classes have demonstrated notable antitumor effects, including inhibiting cell proliferation, promoting apoptosis, modulating the immune response, and suppressing metastasis. These findings suggest the potential of these repurposed drugs as effective therapeutic approaches in cancer treatment. Repurposing approved non-oncology drugs provides a promising strategy for addressing the urgent need for effective and accessible cancer treatments. The diverse classes of repurposed drugs, with their demonstrated antiproliferative, pro-apoptotic, immunomodulatory, and antimetastatic properties, offer new avenues for cancer therapy. Further research and clinical trials are warranted to explore the full potential of these repurposed drugs and optimize their use in treating various cancer types. Repurposing approved drugs can significantly expedite the process of identifying effective treatments and improve patient outcomes in a cost-effective manner